A Highly Effective and Practical Corticosteroid Regimen to Overcome Skin Rash Associated with Immunomodulatory Drugs Allowing Reinstitution of Therapy

Immunomodulatory drugs (IMiDs) are backbone of myeloma therapy in induction and maintenance therapy after transplant for patients (pts) with Multiple Myeloma (MM). The incidence of IMiD-associated rash is up to 27% (Nardone, et al, Clinical Lymphoma Myeloma and Leukemia. 2013) and importantly heralds a favorable prognosis (Kojima, et al. Blood. 2016) suggesting more robust immune stimulation by this class of drugs; however, lack of optimal management strategy of this toxicity can deprive large subset of pts from maintenance therapy after transplant and lead to potential detrimental impact on survivals.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 621 Source Type: research